CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 240 target
Drug / intervention
HMPL-760 +2 moredrug
Likely dose
R-GemOx 375 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07409428
NCT07409428Phase 3RecruitingOn TrackUpdated 3mo ago
CompareCT.gov

A Phase III Randomized, Double-Blind, Positive Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Hutchmed·interventional·Posted Feb 13, 2026·Updated Apr 1, 2026

In Brief

A Phase 3 clinical trial evaluating HMPL-760, HMPL-760 Placebo, and 1 other intervention for Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Currently recruiting, targeting 240 participants across 41 sites.

Detailed Summary

This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsed/Refractory Diffuse Large B-Cell Lymphoma
CountriesChina
Collaborators--

Timeline

Phase 3Recruiting
202720282029
First PostedFeb 13, 2026
Enrollment StartMar 20, 2026
Primary CompletionApr 30, 2028
Study CompletionDec 30, 2028
TodayJul 1, 2026
Enrollment to primary: 2.1 yearsPosted 5 months agoPrimary completion in 1.8 years

Interventions

HMPL-760drug

Patients will receive HMPL-760 once daily (QD) orally.

HMPL-760 Placebodrug

Patients will receive HMPL-760 placebo once daily (QD) orally.

R-GemOxdrug

R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.